Wegovy 7.2 mg: What the Higher Dose Actually Costs

There is a higher dose of Wegovy now, and its label carries a number almost nobody is discussing. Dysesthesia — abnormal skin sensation, which the label defines as covering burning, tingling, heightened sensitivity and skin pain — was reported by 22% of people on 7.2 mg. At 2.4 mg it was 6%. On placebo it was zero.^[1] More than one person in five. If you are weighing this dose against nausea, you are weighing the wrong side effect.

What the table shows

The label reports the 7.2 mg dose against both 2.4 mg and placebo in the same table, which is unusually useful — it lets you see what escalating actually costs rather than what the drug costs in general.^[1]

Read down the last two columns rather than across. Nausea moves four points. Constipation moves one. Dysesthesia moves sixteen, and hair loss doubles. The gastrointestinal effects everyone braces for are largely already priced in by 2.4 mg; what the higher dose adds is mostly something else.

Going from 2.4 to 7.2 mg barely changes the nausea. It nearly quadruples the skin symptoms.

What dysesthesia actually means

It is not a familiar word and the label spells out what it is counting: allodynia, burning sensation, dysesthesia itself, hyperesthesia, hyperpathia, pain of skin, and paresthesia.^[1] In ordinary language — skin that burns, tingles, prickles, feels raw, or hurts at a touch that should not hurt.

That is a sensory nerve symptom rather than a gut one, and it is a different category from everything else on the list. What the label does not say is why it happens, how long it lasts, whether it resolves on stopping, or whether it resolves on dropping back to 2.4 mg. Those are the questions a person with burning skin would ask first, and the label answers none of them.

How you get to this dose at all

The label does not treat 7.2 mg as the destination. It is reached only after tolerating 2.4 mg for at least four weeks, and only where further weight reduction is clinically indicated — with the instruction to weigh both treatment response and tolerability in choosing.^[1]

That is narrower than the way higher doses usually get discussed. It is not a reward for doing well, and it is not the natural end of the ladder. Our titration planner prints the schedule from the label itself.

One thing this table is not

Table 4 has an inclusion rule worth knowing before quoting anything from it: it lists reactions occurring in at least 2% of people and more often than on both 2.4 mg and placebo.^[1]

It is built specifically to show what gets worse at the higher dose. Anything equally common at both doses is not in it. So this is a table about the marginal cost of escalating, not a safety profile of the drug — and reading it as the latter would overstate how unpleasant 7.2 mg is in absolute terms.

For what the doses buy on the other side of that trade, our semaglutide timeline sets out what the trials recorded, and how long side effects last covers the escalation-week pattern.